Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
New peer-reviewed research published in the Journal of the American Medical Association (JAMA) Oncology validates the efficacy of MyProstateScore 2.0 (MPS2). The findings signify a major advancement in the ability to make highly accurate, comprehensive and personalized predictions by raising the performance standard for urine biomarker tests intended to detect clinically significant prostate cancer.
![](https://www.pcmarkers.com/wp-content/uploads/2024/01/Physicians-Weekly-Story-1-e1706209998551-400x200.png)
Physician’s Weekly podcast – The PSA Test Controversy
In a lively discussion, E. David Crawford, MD (University of Colorado), explains the controversy around prostate-specific antigen (PSA) test screening. The National Cancer Institute describes the PSA controversy as follows: “Using the PSA test to screen men for prostate cancer is controversial because it is not yet known for certain whether this test actually saves […]
![](https://www.pcmarkers.com/wp-content/uploads/2024/01/FBIG-are_we_getting_it_wrong-e1706210253543-400x200.png)
Valley News: Are we getting it wrong on prostate cancer screening?
James Heffernan, an emeritus professor of English at Dartmouth College, speaks of his experience with prostate cancer and makes a case for early detection through prostate cancer biomarkers.
![](https://www.pcmarkers.com/wp-content/uploads/2024/01/image-1-e1706209900676-400x200.png)
Living Your Healthiest Life By Understanding Your Prostate Cancer Risk
Learn more about how routine PSA testing can be a critical part of living your healthiest life!
The PSA Test Controversy, Doctor Vs Insurer on Settlements
In a lively recorded discussion, E. David Crawford MD explains the controversy around prostate-specific antigen (PSA) test screening. Listen to the full conversation on this episode of the Physician’s Weekly podcast.
![](https://www.pcmarkers.com/wp-content/uploads/2023/11/9-news-400x200.png)
9News: Health officials urge people to get preventative screenings for prostate cancer
Dr. E. David Crawford, MD, on a featured story for CBS 9 News in Denver, Colorado regarding early PSA screening.
Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
Both Caucasian and African American men with baseline PSA values between 1.5 and 4.0 ng/mL are at increased risk for future prostate cancer compared with those who have an initial PSA value below the 1.5 ng/mL threshold. Based on a growing body of literature and this analysis, it is recommended that a first PSA test threshold of 1.5 ng/mL and above, or somewhere between 1.5 and 4.0 ng/mL, represent the Early-Warning PSA Zone (EWP Zone).
96% Negative Predictive Value for High-grade Cancer
This study shows that, when compared to other risk factors, detection of DNA-methylation in histopathologically negative biopsies was the most significant and important predictor of high-grade cancer, resulting in a negative predictive value of 96%.
Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome
ExoDx Prostate IntelliScore (EPI) is a non-invasive urine exosome RNA-based test for risk assessment of high-grade prostate cancer. We evaluated the association of pre-biopsy test results with post-radical prostatectomy (RP) outcomes to understand the potential utility of EPI to inform invasive treatment vs active surveillance (AS) decisions.
Beyond PSA: The Role of Prostate Health Index (phi)
Literature data showed that phi had good diagnostic performance to identify clinically significant (cs) PCa, suggesting that it could be a useful tool for personalized treatment decision-making. In this review, phi potentialities, limitations, and comparisons with other blood- and urinary-based tests were explored.